Bolt Biotherapeutics
Chi-Ling Fu is a Senior Scientist at Bolt Biotherapeutics, Inc., where professional responsibilities include driving in vivo pharmacology strategies. Previously, at AbbVie, Chi-Ling held the position of Senior Scientist II, leading in vivo pharmacology efforts in various tumor models. At Pharmacyclics, Chi-Ling advanced the understanding of mechanisms of action for small molecule drugs in oncology and developed pharmacodynamic assays. Prior experience includes roles at NGM Biopharmaceuticals and Stanford University School of Medicine, focusing on immuno-oncology and inflammatory disease models, respectively. Chi-Ling holds a PhD and Master's degree in Immunology, as well as a Bachelor's degree in Agricultural Chemistry, all obtained from National Taiwan University.
This person is not in any teams
Bolt Biotherapeutics
7 followers
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients.